Back to top
more

ModivCare (MODV)

(Delayed Data from NSDQ)

$23.84 USD

23.84
115,840

+0.28 (1.19%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $23.87 +0.03 (0.13%) 7:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alignment Healthcare (ALHC) Surges 17.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Alignment Healthcare (ALHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ModivCare (MODV) Misses Q2 Earnings Estimates

by Zacks Equity Research

ModivCare (MODV) delivered earnings and revenue surprises of -2.65% and 7.90%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ModivCare (MODV) Misses Q1 Earnings Estimates

by Zacks Equity Research

ModivCare (MODV) delivered earnings and revenue surprises of -4.05% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ModivCare (MODV) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

ModivCare (MODV) delivered earnings and revenue surprises of 35.26% and 6.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Charles River Laboratories (CRL) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Charles River (CRL) delivered earnings and revenue surprises of 8.36% and 5.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ModivCare (MODV) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

ModivCare (MODV) delivered earnings and revenue surprises of 6.62% and 9.98%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Investors Undervaluing ModivCare (MODV) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy AMN Healthcare Services (AMN) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Shaun Pruitt headshot

3 Top Ranked Stocks for Exposure to the Medical Sector

by Shaun Pruitt

The healthcare business offers attractive defensive attributes that are so valuable in the current uncertain environment. As such, adding healthcare stocks to the portfolio brings much needed diversification.

Zacks Industry Outlook Highlights HealthEquity, AMN Healthcare and ModivCare

by Zacks Equity Research

HealthEquity, AMN Healthcare and ModivCare have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Services Stocks Braving Near-Term Industry Headwinds

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, AMN and MODV are set to gain the most. However, staffing shortages may disrupt the trend.

MODV vs. PGNY: Which Stock Is the Better Value Option?

by Zacks Equity Research

MODV vs. PGNY: Which Stock Is the Better Value Option?

Zacks.com featured highlights include BorgWarner Univar Solutions, Marathon Petroleum, Barclays and ModivCare

by Zacks Equity Research

BorgWarner, Univar Solutions, Marathon Petroleum, Barclays and ModivCare are part of Zacks Screen of the Week article.

Urmimala Biswas headshot

5 Best Value Stocks Based on Discounted PEG Ratio

by Urmimala Biswas

Here are five stocks, BWA, UNVR, MPC, BCS and MODV, which qualify our value-based screening criteria.

Can ModivCare (MODV) Climb 29% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 28.5% upside potential for ModivCare (MODV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MODV vs. PGNY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

MODV vs. PGNY: Which Stock Is the Better Value Option?

Best Momentum Stocks to Buy for August 10th

by Zacks Equity Research

TTMI, CIGI and MODV made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 10, 2022.

    Does ModivCare (MODV) Have the Potential to Rally 32% as Wall Street Analysts Expect?

    by Zacks Equity Research

    The mean of analysts' price targets for ModivCare (MODV) points to a 31.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

    ModivCare (MODV) Q2 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    ModivCare (MODV) delivered earnings and revenue surprises of 39.16% and 7.99%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Doximity (DOCS) Surges 6.6%: Is This an Indication of Further Gains?

    by Zacks Equity Research

    Doximity (DOCS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

    ModivCare (MODV) Q1 Earnings Lag Estimates

    by Zacks Equity Research

    ModivCare (MODV) delivered earnings and revenue surprises of -0.63% and 1.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: ModivCare (MODV) Q1 Earnings Expected to Decline

    by Zacks Equity Research

    ModivCare (MODV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Medpace (MEDP) Q1 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Medpace (MEDP) delivered earnings and revenue surprises of 34.13% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    ModivCare (MODV) Q4 Earnings and Revenues Top Estimates

    by Zacks Equity Research

    ModivCare (MODV) delivered earnings and revenue surprises of 28.66% and 4.12%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    CareDx (CDNA) delivered earnings and revenue surprises of -250% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?